aTyr Pharma regains compliance with Nasdaq minimum bid price requirement
ATYR•aTyr Pharma said it regained compliance with Nasdaq’s minimum bid price requirement after its common stock closed at $1 or higher for 10 consecutive business days from October 30 through November 12, 2026. No Nasdaq deficiency notices remained outstanding as of the filing date.
1. Compliance restored
aTyr Pharma said it received notice on November 13, 2026, that it regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement. Its common stock closed at $1 or higher for 10 consecutive business days from October 30 through November 12, and no Nasdaq deficiency notices remained outstanding as of the filing date.
